

1502  
Kishore

1502

**MCGREGOR & ADLER**  
A PROFESSIONAL CORPORATION

RECEIVED  
1-14-98

P.O. BOX 710509  
HOUSTON, TEXAS 77271-0509

WRITER'S DIRECT DIAL  
(713)-777-2321  
WRITER'S DIRECT FACS.  
(713)-777-6908  
E. MAIL: BAADLER@i-link.net

INTELLECTUAL PROPERTY LAW  
(PATENT, BIOTECHNOLOGY, COMPUTER,  
TRADEMARK & TRADE SECRET LAW)

January 14, 1998

**FACSIMILE COVER SHEET**

PLEASE DELIVER TO: Examiner G.S. Kishore, Ph.D.

COMPANY: USPTO-Group 1502

FACSIMILE NUMBER: (703) 305-5408

NUMBER OF PAGES (COUNTING COVER SHEET): 7

FROM: Dr. Benjamin Adler

MESSAGE: Please deliver to Examiner Kishore. Thanks, Dr. Adler

**CONFIDENTIALITY NOTICE:** Unless otherwise indicated or obvious from the nature of this transmittal, the information contained in this facsimile is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader is not the intended recipient or an employee or agent responsible for delivery, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please immediately notify Dr. Benjamin Adler at (713) 777-2321 and promptly return the facsimile. Thank you.

*8/ Reg for  
Recons*

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:  
T. STEINEMANN ET AL.§  
§  
§  
§  
§  
§  
§  
§

ART UNIT: 1502

FILED: May 4, 1994

EXAMINER:  
KISHORE, G.

SERIAL NO.: 08/580,384

FOR: NOVEL OPHTHALMOLOGIC  
USES OF PROTEIN C

DOCKET: D5715D

*Ref*  
*-21-98*  
**RECEIVED**  
*1-14-98*Assistant Commissioner of Patents  
BOX NON-FEE  
Washington, D.C. 20231

## CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this Response is being transmitted via facsimile to  
the Patent Office on January 14, 1998.*Benjamin Aaron Adler*  
Benjamin Aaron Adler, Ph.D., J.D.

## RESPONSE

Dear Sir:

Responsive to the Final Office Action mailed October 14, 1997,  
please enter the following amendments.REMARKSApplicant submits the following remarks. Reconsideration of  
this application in view of the remarks is respectfully requested.The 35 USC §103 RejectionsClaims 22-27 stand rejected under 35 USC §103(a) as being  
unpatentable over **Galin** et al. or **Iverson** et al. in combination with **Bang**  
et al. and **Esmon** et al. Claims 28-29 stand rejected under 35 USC §103(a)  
as being unpatentable over **Galin** et al. or **Iverson** et al. in combination